Revisiting a Null Hypothesis: Exploring the Parameters of Oligometastasis Treatment
In the treatment of patients with metastatic cancer, the current paradigm states that metastasis-directed therapy does not prolong life. This paradigm forms the basis of clinical trial null hypotheses, where trials are built to test the null hypothesis that patients garner no overall survival benefi...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Scarborough, Jessica A. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021transfer abstract |
|---|
| Umfang: |
11 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Xiaokeping-induced autophagy protects pancreatic β-cells against apoptosis under high glucose stress - Wu, Yanyang ELSEVIER, 2018, the official journal of the American Society for Therapeutic Radiology and Oncology, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:110 ; year:2021 ; number:2 ; day:1 ; month:06 ; pages:371-381 ; extent:11 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ijrobp.2020.12.044 |
|---|
| Katalog-ID: |
ELV053977270 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV053977270 | ||
| 003 | DE-627 | ||
| 005 | 20230626035528.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210910s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijrobp.2020.12.044 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001418.pica |
| 035 | |a (DE-627)ELV053977270 | ||
| 035 | |a (ELSEVIER)S0360-3016(20)34740-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Scarborough, Jessica A. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Revisiting a Null Hypothesis: Exploring the Parameters of Oligometastasis Treatment |
| 264 | 1 | |c 2021transfer abstract | |
| 300 | |a 11 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a In the treatment of patients with metastatic cancer, the current paradigm states that metastasis-directed therapy does not prolong life. This paradigm forms the basis of clinical trial null hypotheses, where trials are built to test the null hypothesis that patients garner no overall survival benefit from targeting metastatic lesions. However, with advancing imaging technology and increasingly precise techniques for targeting lesions, a much larger proportion of metastatic disease can be treated. As a result, the life-extending benefit of targeting metastatic disease is becoming increasingly clear. | ||
| 520 | |a In the treatment of patients with metastatic cancer, the current paradigm states that metastasis-directed therapy does not prolong life. This paradigm forms the basis of clinical trial null hypotheses, where trials are built to test the null hypothesis that patients garner no overall survival benefit from targeting metastatic lesions. However, with advancing imaging technology and increasingly precise techniques for targeting lesions, a much larger proportion of metastatic disease can be treated. As a result, the life-extending benefit of targeting metastatic disease is becoming increasingly clear. | ||
| 700 | 1 | |a Tom, Martin C. |4 oth | |
| 700 | 1 | |a Kattan, Michael W. |4 oth | |
| 700 | 1 | |a Scott, Jacob G. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Wu, Yanyang ELSEVIER |t Xiaokeping-induced autophagy protects pancreatic β-cells against apoptosis under high glucose stress |d 2018 |d the official journal of the American Society for Therapeutic Radiology and Oncology |g Amsterdam [u.a.] |w (DE-627)ELV000113948 |
| 773 | 1 | 8 | |g volume:110 |g year:2021 |g number:2 |g day:1 |g month:06 |g pages:371-381 |g extent:11 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijrobp.2020.12.044 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.40 |j Pharmazie |j Pharmazeutika |q VZ |
| 951 | |a AR | ||
| 952 | |d 110 |j 2021 |e 2 |b 1 |c 0601 |h 371-381 |g 11 | ||
| author_variant |
j a s ja jas |
|---|---|
| matchkey_str |
scarboroughjessicaatommartinckattanmicha:2021----:eiiignlhpteiepoighprmtrooio |
| hierarchy_sort_str |
2021transfer abstract |
| bklnumber |
44.40 |
| publishDate |
2021 |
| allfields |
10.1016/j.ijrobp.2020.12.044 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001418.pica (DE-627)ELV053977270 (ELSEVIER)S0360-3016(20)34740-4 DE-627 ger DE-627 rakwb eng 610 VZ 44.40 bkl Scarborough, Jessica A. verfasserin aut Revisiting a Null Hypothesis: Exploring the Parameters of Oligometastasis Treatment 2021transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In the treatment of patients with metastatic cancer, the current paradigm states that metastasis-directed therapy does not prolong life. This paradigm forms the basis of clinical trial null hypotheses, where trials are built to test the null hypothesis that patients garner no overall survival benefit from targeting metastatic lesions. However, with advancing imaging technology and increasingly precise techniques for targeting lesions, a much larger proportion of metastatic disease can be treated. As a result, the life-extending benefit of targeting metastatic disease is becoming increasingly clear. In the treatment of patients with metastatic cancer, the current paradigm states that metastasis-directed therapy does not prolong life. This paradigm forms the basis of clinical trial null hypotheses, where trials are built to test the null hypothesis that patients garner no overall survival benefit from targeting metastatic lesions. However, with advancing imaging technology and increasingly precise techniques for targeting lesions, a much larger proportion of metastatic disease can be treated. As a result, the life-extending benefit of targeting metastatic disease is becoming increasingly clear. Tom, Martin C. oth Kattan, Michael W. oth Scott, Jacob G. oth Enthalten in Elsevier Science Wu, Yanyang ELSEVIER Xiaokeping-induced autophagy protects pancreatic β-cells against apoptosis under high glucose stress 2018 the official journal of the American Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV000113948 volume:110 year:2021 number:2 day:1 month:06 pages:371-381 extent:11 https://doi.org/10.1016/j.ijrobp.2020.12.044 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-PHA 44.40 Pharmazie Pharmazeutika VZ AR 110 2021 2 1 0601 371-381 11 |
| spelling |
10.1016/j.ijrobp.2020.12.044 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001418.pica (DE-627)ELV053977270 (ELSEVIER)S0360-3016(20)34740-4 DE-627 ger DE-627 rakwb eng 610 VZ 44.40 bkl Scarborough, Jessica A. verfasserin aut Revisiting a Null Hypothesis: Exploring the Parameters of Oligometastasis Treatment 2021transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In the treatment of patients with metastatic cancer, the current paradigm states that metastasis-directed therapy does not prolong life. This paradigm forms the basis of clinical trial null hypotheses, where trials are built to test the null hypothesis that patients garner no overall survival benefit from targeting metastatic lesions. However, with advancing imaging technology and increasingly precise techniques for targeting lesions, a much larger proportion of metastatic disease can be treated. As a result, the life-extending benefit of targeting metastatic disease is becoming increasingly clear. In the treatment of patients with metastatic cancer, the current paradigm states that metastasis-directed therapy does not prolong life. This paradigm forms the basis of clinical trial null hypotheses, where trials are built to test the null hypothesis that patients garner no overall survival benefit from targeting metastatic lesions. However, with advancing imaging technology and increasingly precise techniques for targeting lesions, a much larger proportion of metastatic disease can be treated. As a result, the life-extending benefit of targeting metastatic disease is becoming increasingly clear. Tom, Martin C. oth Kattan, Michael W. oth Scott, Jacob G. oth Enthalten in Elsevier Science Wu, Yanyang ELSEVIER Xiaokeping-induced autophagy protects pancreatic β-cells against apoptosis under high glucose stress 2018 the official journal of the American Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV000113948 volume:110 year:2021 number:2 day:1 month:06 pages:371-381 extent:11 https://doi.org/10.1016/j.ijrobp.2020.12.044 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-PHA 44.40 Pharmazie Pharmazeutika VZ AR 110 2021 2 1 0601 371-381 11 |
| allfields_unstemmed |
10.1016/j.ijrobp.2020.12.044 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001418.pica (DE-627)ELV053977270 (ELSEVIER)S0360-3016(20)34740-4 DE-627 ger DE-627 rakwb eng 610 VZ 44.40 bkl Scarborough, Jessica A. verfasserin aut Revisiting a Null Hypothesis: Exploring the Parameters of Oligometastasis Treatment 2021transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In the treatment of patients with metastatic cancer, the current paradigm states that metastasis-directed therapy does not prolong life. This paradigm forms the basis of clinical trial null hypotheses, where trials are built to test the null hypothesis that patients garner no overall survival benefit from targeting metastatic lesions. However, with advancing imaging technology and increasingly precise techniques for targeting lesions, a much larger proportion of metastatic disease can be treated. As a result, the life-extending benefit of targeting metastatic disease is becoming increasingly clear. In the treatment of patients with metastatic cancer, the current paradigm states that metastasis-directed therapy does not prolong life. This paradigm forms the basis of clinical trial null hypotheses, where trials are built to test the null hypothesis that patients garner no overall survival benefit from targeting metastatic lesions. However, with advancing imaging technology and increasingly precise techniques for targeting lesions, a much larger proportion of metastatic disease can be treated. As a result, the life-extending benefit of targeting metastatic disease is becoming increasingly clear. Tom, Martin C. oth Kattan, Michael W. oth Scott, Jacob G. oth Enthalten in Elsevier Science Wu, Yanyang ELSEVIER Xiaokeping-induced autophagy protects pancreatic β-cells against apoptosis under high glucose stress 2018 the official journal of the American Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV000113948 volume:110 year:2021 number:2 day:1 month:06 pages:371-381 extent:11 https://doi.org/10.1016/j.ijrobp.2020.12.044 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-PHA 44.40 Pharmazie Pharmazeutika VZ AR 110 2021 2 1 0601 371-381 11 |
| allfieldsGer |
10.1016/j.ijrobp.2020.12.044 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001418.pica (DE-627)ELV053977270 (ELSEVIER)S0360-3016(20)34740-4 DE-627 ger DE-627 rakwb eng 610 VZ 44.40 bkl Scarborough, Jessica A. verfasserin aut Revisiting a Null Hypothesis: Exploring the Parameters of Oligometastasis Treatment 2021transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In the treatment of patients with metastatic cancer, the current paradigm states that metastasis-directed therapy does not prolong life. This paradigm forms the basis of clinical trial null hypotheses, where trials are built to test the null hypothesis that patients garner no overall survival benefit from targeting metastatic lesions. However, with advancing imaging technology and increasingly precise techniques for targeting lesions, a much larger proportion of metastatic disease can be treated. As a result, the life-extending benefit of targeting metastatic disease is becoming increasingly clear. In the treatment of patients with metastatic cancer, the current paradigm states that metastasis-directed therapy does not prolong life. This paradigm forms the basis of clinical trial null hypotheses, where trials are built to test the null hypothesis that patients garner no overall survival benefit from targeting metastatic lesions. However, with advancing imaging technology and increasingly precise techniques for targeting lesions, a much larger proportion of metastatic disease can be treated. As a result, the life-extending benefit of targeting metastatic disease is becoming increasingly clear. Tom, Martin C. oth Kattan, Michael W. oth Scott, Jacob G. oth Enthalten in Elsevier Science Wu, Yanyang ELSEVIER Xiaokeping-induced autophagy protects pancreatic β-cells against apoptosis under high glucose stress 2018 the official journal of the American Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV000113948 volume:110 year:2021 number:2 day:1 month:06 pages:371-381 extent:11 https://doi.org/10.1016/j.ijrobp.2020.12.044 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-PHA 44.40 Pharmazie Pharmazeutika VZ AR 110 2021 2 1 0601 371-381 11 |
| allfieldsSound |
10.1016/j.ijrobp.2020.12.044 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001418.pica (DE-627)ELV053977270 (ELSEVIER)S0360-3016(20)34740-4 DE-627 ger DE-627 rakwb eng 610 VZ 44.40 bkl Scarborough, Jessica A. verfasserin aut Revisiting a Null Hypothesis: Exploring the Parameters of Oligometastasis Treatment 2021transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In the treatment of patients with metastatic cancer, the current paradigm states that metastasis-directed therapy does not prolong life. This paradigm forms the basis of clinical trial null hypotheses, where trials are built to test the null hypothesis that patients garner no overall survival benefit from targeting metastatic lesions. However, with advancing imaging technology and increasingly precise techniques for targeting lesions, a much larger proportion of metastatic disease can be treated. As a result, the life-extending benefit of targeting metastatic disease is becoming increasingly clear. In the treatment of patients with metastatic cancer, the current paradigm states that metastasis-directed therapy does not prolong life. This paradigm forms the basis of clinical trial null hypotheses, where trials are built to test the null hypothesis that patients garner no overall survival benefit from targeting metastatic lesions. However, with advancing imaging technology and increasingly precise techniques for targeting lesions, a much larger proportion of metastatic disease can be treated. As a result, the life-extending benefit of targeting metastatic disease is becoming increasingly clear. Tom, Martin C. oth Kattan, Michael W. oth Scott, Jacob G. oth Enthalten in Elsevier Science Wu, Yanyang ELSEVIER Xiaokeping-induced autophagy protects pancreatic β-cells against apoptosis under high glucose stress 2018 the official journal of the American Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV000113948 volume:110 year:2021 number:2 day:1 month:06 pages:371-381 extent:11 https://doi.org/10.1016/j.ijrobp.2020.12.044 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-PHA 44.40 Pharmazie Pharmazeutika VZ AR 110 2021 2 1 0601 371-381 11 |
| language |
English |
| source |
Enthalten in Xiaokeping-induced autophagy protects pancreatic β-cells against apoptosis under high glucose stress Amsterdam [u.a.] volume:110 year:2021 number:2 day:1 month:06 pages:371-381 extent:11 |
| sourceStr |
Enthalten in Xiaokeping-induced autophagy protects pancreatic β-cells against apoptosis under high glucose stress Amsterdam [u.a.] volume:110 year:2021 number:2 day:1 month:06 pages:371-381 extent:11 |
| format_phy_str_mv |
Article |
| bklname |
Pharmazie Pharmazeutika |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Xiaokeping-induced autophagy protects pancreatic β-cells against apoptosis under high glucose stress |
| authorswithroles_txt_mv |
Scarborough, Jessica A. @@aut@@ Tom, Martin C. @@oth@@ Kattan, Michael W. @@oth@@ Scott, Jacob G. @@oth@@ |
| publishDateDaySort_date |
2021-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000113948 |
| dewey-sort |
3610 |
| id |
ELV053977270 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV053977270</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626035528.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ijrobp.2020.12.044</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001418.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV053977270</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0360-3016(20)34740-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Scarborough, Jessica A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Revisiting a Null Hypothesis: Exploring the Parameters of Oligometastasis Treatment</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">11</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In the treatment of patients with metastatic cancer, the current paradigm states that metastasis-directed therapy does not prolong life. This paradigm forms the basis of clinical trial null hypotheses, where trials are built to test the null hypothesis that patients garner no overall survival benefit from targeting metastatic lesions. However, with advancing imaging technology and increasingly precise techniques for targeting lesions, a much larger proportion of metastatic disease can be treated. As a result, the life-extending benefit of targeting metastatic disease is becoming increasingly clear.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In the treatment of patients with metastatic cancer, the current paradigm states that metastasis-directed therapy does not prolong life. This paradigm forms the basis of clinical trial null hypotheses, where trials are built to test the null hypothesis that patients garner no overall survival benefit from targeting metastatic lesions. However, with advancing imaging technology and increasingly precise techniques for targeting lesions, a much larger proportion of metastatic disease can be treated. As a result, the life-extending benefit of targeting metastatic disease is becoming increasingly clear.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tom, Martin C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kattan, Michael W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Scott, Jacob G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Wu, Yanyang ELSEVIER</subfield><subfield code="t">Xiaokeping-induced autophagy protects pancreatic β-cells against apoptosis under high glucose stress</subfield><subfield code="d">2018</subfield><subfield code="d">the official journal of the American Society for Therapeutic Radiology and Oncology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000113948</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:110</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:2</subfield><subfield code="g">day:1</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:371-381</subfield><subfield code="g">extent:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ijrobp.2020.12.044</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="j">Pharmazie</subfield><subfield code="j">Pharmazeutika</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">110</subfield><subfield code="j">2021</subfield><subfield code="e">2</subfield><subfield code="b">1</subfield><subfield code="c">0601</subfield><subfield code="h">371-381</subfield><subfield code="g">11</subfield></datafield></record></collection>
|
| author |
Scarborough, Jessica A. |
| spellingShingle |
Scarborough, Jessica A. ddc 610 bkl 44.40 Revisiting a Null Hypothesis: Exploring the Parameters of Oligometastasis Treatment |
| authorStr |
Scarborough, Jessica A. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000113948 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.40 bkl Revisiting a Null Hypothesis: Exploring the Parameters of Oligometastasis Treatment |
| topic |
ddc 610 bkl 44.40 |
| topic_unstemmed |
ddc 610 bkl 44.40 |
| topic_browse |
ddc 610 bkl 44.40 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m c t mc mct m w k mw mwk j g s jg jgs |
| hierarchy_parent_title |
Xiaokeping-induced autophagy protects pancreatic β-cells against apoptosis under high glucose stress |
| hierarchy_parent_id |
ELV000113948 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Xiaokeping-induced autophagy protects pancreatic β-cells against apoptosis under high glucose stress |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000113948 |
| title |
Revisiting a Null Hypothesis: Exploring the Parameters of Oligometastasis Treatment |
| ctrlnum |
(DE-627)ELV053977270 (ELSEVIER)S0360-3016(20)34740-4 |
| title_full |
Revisiting a Null Hypothesis: Exploring the Parameters of Oligometastasis Treatment |
| author_sort |
Scarborough, Jessica A. |
| journal |
Xiaokeping-induced autophagy protects pancreatic β-cells against apoptosis under high glucose stress |
| journalStr |
Xiaokeping-induced autophagy protects pancreatic β-cells against apoptosis under high glucose stress |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
zzz |
| container_start_page |
371 |
| author_browse |
Scarborough, Jessica A. |
| container_volume |
110 |
| physical |
11 |
| class |
610 VZ 44.40 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Scarborough, Jessica A. |
| doi_str_mv |
10.1016/j.ijrobp.2020.12.044 |
| dewey-full |
610 |
| title_sort |
revisiting a null hypothesis: exploring the parameters of oligometastasis treatment |
| title_auth |
Revisiting a Null Hypothesis: Exploring the Parameters of Oligometastasis Treatment |
| abstract |
In the treatment of patients with metastatic cancer, the current paradigm states that metastasis-directed therapy does not prolong life. This paradigm forms the basis of clinical trial null hypotheses, where trials are built to test the null hypothesis that patients garner no overall survival benefit from targeting metastatic lesions. However, with advancing imaging technology and increasingly precise techniques for targeting lesions, a much larger proportion of metastatic disease can be treated. As a result, the life-extending benefit of targeting metastatic disease is becoming increasingly clear. |
| abstractGer |
In the treatment of patients with metastatic cancer, the current paradigm states that metastasis-directed therapy does not prolong life. This paradigm forms the basis of clinical trial null hypotheses, where trials are built to test the null hypothesis that patients garner no overall survival benefit from targeting metastatic lesions. However, with advancing imaging technology and increasingly precise techniques for targeting lesions, a much larger proportion of metastatic disease can be treated. As a result, the life-extending benefit of targeting metastatic disease is becoming increasingly clear. |
| abstract_unstemmed |
In the treatment of patients with metastatic cancer, the current paradigm states that metastasis-directed therapy does not prolong life. This paradigm forms the basis of clinical trial null hypotheses, where trials are built to test the null hypothesis that patients garner no overall survival benefit from targeting metastatic lesions. However, with advancing imaging technology and increasingly precise techniques for targeting lesions, a much larger proportion of metastatic disease can be treated. As a result, the life-extending benefit of targeting metastatic disease is becoming increasingly clear. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-PHA |
| container_issue |
2 |
| title_short |
Revisiting a Null Hypothesis: Exploring the Parameters of Oligometastasis Treatment |
| url |
https://doi.org/10.1016/j.ijrobp.2020.12.044 |
| remote_bool |
true |
| author2 |
Tom, Martin C. Kattan, Michael W. Scott, Jacob G. |
| author2Str |
Tom, Martin C. Kattan, Michael W. Scott, Jacob G. |
| ppnlink |
ELV000113948 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1016/j.ijrobp.2020.12.044 |
| up_date |
2024-07-06T20:25:56.619Z |
| _version_ |
1803862730729324544 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV053977270</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626035528.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ijrobp.2020.12.044</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001418.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV053977270</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0360-3016(20)34740-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Scarborough, Jessica A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Revisiting a Null Hypothesis: Exploring the Parameters of Oligometastasis Treatment</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">11</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In the treatment of patients with metastatic cancer, the current paradigm states that metastasis-directed therapy does not prolong life. This paradigm forms the basis of clinical trial null hypotheses, where trials are built to test the null hypothesis that patients garner no overall survival benefit from targeting metastatic lesions. However, with advancing imaging technology and increasingly precise techniques for targeting lesions, a much larger proportion of metastatic disease can be treated. As a result, the life-extending benefit of targeting metastatic disease is becoming increasingly clear.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In the treatment of patients with metastatic cancer, the current paradigm states that metastasis-directed therapy does not prolong life. This paradigm forms the basis of clinical trial null hypotheses, where trials are built to test the null hypothesis that patients garner no overall survival benefit from targeting metastatic lesions. However, with advancing imaging technology and increasingly precise techniques for targeting lesions, a much larger proportion of metastatic disease can be treated. As a result, the life-extending benefit of targeting metastatic disease is becoming increasingly clear.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tom, Martin C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kattan, Michael W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Scott, Jacob G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Wu, Yanyang ELSEVIER</subfield><subfield code="t">Xiaokeping-induced autophagy protects pancreatic β-cells against apoptosis under high glucose stress</subfield><subfield code="d">2018</subfield><subfield code="d">the official journal of the American Society for Therapeutic Radiology and Oncology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000113948</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:110</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:2</subfield><subfield code="g">day:1</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:371-381</subfield><subfield code="g">extent:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ijrobp.2020.12.044</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="j">Pharmazie</subfield><subfield code="j">Pharmazeutika</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">110</subfield><subfield code="j">2021</subfield><subfield code="e">2</subfield><subfield code="b">1</subfield><subfield code="c">0601</subfield><subfield code="h">371-381</subfield><subfield code="g">11</subfield></datafield></record></collection>
|
| score |
7.400074 |